4.8 Article

IκB Kinase 2 Is Essential for IgE-Induced Mast Cell De Novo Cytokine Production but Not for Degranulation

Journal

CELL REPORTS
Volume 8, Issue 5, Pages 1300-1307

Publisher

CELL PRESS
DOI: 10.1016/j.celrep.2014.07.046

Keywords

-

Categories

Funding

  1. DFG [RO2133/7-1, RO2133/4-1, RO2133/5-1, RO2133/5-2, SCHM 2440/1, DU1172/1, DU1172/2, DU1172/3-2]
  2. Boehringer Ingelheim Fonds PhD fellowship

Ask authors/readers for more resources

The immunoglobulin E (IgE)-mediated mast cell (MC) response is central to the pathogenesis of type I allergy and asthma. I kappa B kinase 2 (IKK2) was reported to couple IgE-induced signals to MC degranulation by phosphorylating the SNARE protein SNAP23. We investigated MC responses in mice with MC-specific inactivation of IKK2 or NF-kappa B essential modulator (NEMO), or animals with MC-specific expression of a mutant, constitutively active IKK2. We show that the IgE-induced late-phase cytokine response is reduced in mice lacking IKK2 or NEMO in MCs. However, anaphylactic in vivo responses of these animals are not different from those of control mice, and in vitro IKK2-deficient MCs readily phosphorylate SNAP23 and degranulate similarly to control cells in response to allergen or calcium ionophore. Constitutive overactivation of the NF-kappa B pathway has only slight effects on allergen-triggered MC responses. Thus, IKK2 is dispensable for MC degranulation, and the important question how IgE-induced signals trigger MC vesicle fusion remains open.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Allergy

Outcomes of COVID-19 vaccination in 323 patients with clonal and non-clonal mast cell activation disorders

Matthew P. Giannetti, Francesco Olivieri, Grace Godwin, Emma Weller, Jennifer Nicoloro-SantaBarbara, Patrizia Bonadonna, Roberta Zanotti, Giovanna Zanoni, Karin Hartmann, Mariana Castells

ALLERGY (2023)

Article Hematology

Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry

Vanessa E. Kennedy, Cecelia Perkins, Andreas Reiter, Mohamad Jawhar, Johannes Luebke, Hanneke C. Kluin-Nelemans, William Shomali, Cheryl Langford, Justin Abuel, Olivier Hermine, Marek Niedoszytko, Aleksandra Gorska, Andrzej Mital, Patrizia Bonadonna, Roberta Zanotti, Ilaria Tanasi, Mattias Mattsson, Hans Hagglund, Massimo Triggiani, Akif Selim Yavuz, Jens Panse, Deborah Christen, Marc Heizmann, Khalid Shoumariyeh, Sabine Mueller, Chiara Elena, Luca Malcovati, Nicolas Fiorelli, Friederike Wortmann, Vladan Vucinic, Knut Brockow, Christos Fokoloros, Sotirios G. Papageorgiou, Christine Breynaert, Dominique Bullens, Michael Doubek, Anja Ilerhaus, Irena Angelova-Fischer, Oleksii Solomianyi, Judit Varkonyi, Vito Sabato, Axel Ruefer, Tanja Daniela Schug, Maud A. W. Hermans, Anna Belloni Fortina, Francesca Caroppo, Horia Bumbea, Theo Gulen, Karin Hartmann, Hanneke Oude Elberink, Juliana Schwaab, Michel Arock, Peter Valent, Wolfgang R. Sperr, Jason Gotlib

Summary: This study evaluated 92 patients with mast cell leukemia (MCL) and found that 34% of patients had an associated hematologic neoplasm. Some patients had chronic MCL, while a small percentage had leukemic MCL. The study also identified genetic mutations and treatment strategies that were associated with prognosis.

BLOOD ADVANCES (2023)

Editorial Material Allergy

Legends of Allergy and Immunology-Dean D. Metcalfe

Cem Akin, Knut Brockow, Karin Hartmann, Gunnar P. P. Nilsson

ALLERGY (2023)

Article Biochemistry & Molecular Biology

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer

Christian Schneeweis, Sandra Diersch, Zonera Hassan, Lukas Krauss, Carolin Schneider, Daniele Lucarelli, Chiara Falcomata, Katja Steiger, Rupert Oellinger, Oliver H. Kraemer, Alexander Arlt, Marian Grade, Marc Schmidt-Supprian, Elisabeth Hessmann, Matthias Wirth, Roland Rad, Maximilian Reichert, Dieter Saur, Guenter Schneider

Summary: This study identifies FRA1 as a regulator of sensitivity to RAF-MEK-ERK inhibitors in pancreatic cancer. FRA1 is associated with the adaptive rewiring of oncogenic ERK signaling and its degradation synergizes with MEK inhibitors.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

Article Physiology

Durability in Professional Cyclists: A Field Study

Pedro L. Valenzuela, Lidia B. Alejo, Laureano M. Ozcoidi, Alejandro Lucia, Alfredo Santalla, David Barranco-Gil

Summary: The purpose of this study was to assess the durability of professional cyclists and potential associated indicators. Twelve male professional cyclists participated in the study and performed a 20-minute time trial on two different sessions. The study found that performance is significantly impaired after a certain amount of work completed, and this impairment is not related to traditional laboratory-based endurance indicators or training load markers.

INTERNATIONAL JOURNAL OF SPORTS PHYSIOLOGY AND PERFORMANCE (2023)

Article Cell Biology

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma

Silke Lambing, Yu Pan Tan, Paraskevi Vasileiadou, Stefan Holdenrieder, Patrick Mueller, Christian Hagen, Stephan Garbe, Rayk Behrendt, Martin Schlee, Jasper G. van den Boorn, Eva Bartok, Marcel Renn, Gunther Hartmann

Summary: Radiotherapy induces DNA damage and activates cell death pathways, but its effectiveness is limited in radioresistant tumors such as melanoma. This study shows that activation of the immune sensing receptor RIG-I can enhance irradiation-induced tumor cell death, leading to improved survival in melanoma models. The results suggest that combining RIG-I ligands with radiotherapy may be a promising approach for treating radioresistant tumors with functional p53 pathways, such as melanoma.

JOURNAL OF MOLECULAR CELL BIOLOGY (2023)

Review Medicine, General & Internal

Alpha-gal syndrome initially misdiagnosed as chronic spontaneous urticaria in a pediatric patient: a case report and review of the literature

Felicitas Bellutti Enders, Marius Elkuch, Andreas Woerner, Kathrin Scherer Hofmeier, Karin Hartmann

Summary: This case report describes a 7-year-old boy who presented with recurrent wheals and was diagnosed with alpha-gal syndrome. Initial suspicion was chronic spontaneous urticaria, but further investigation revealed a history of tick bites and elevated IgE levels for alpha-gal. The case highlights the importance of recognizing alpha-gal syndrome in children, as it is typically seen in adults and often overlooked in pediatric patients.

JOURNAL OF MEDICAL CASE REPORTS (2023)

Article Pediatrics

Mastocytosis in children

Hanna Wassmer, Karin Hartmann

Summary: Mastocytosis in children is a rare disease characterized by abnormal accumulation of tissue mast cells, typically presenting with skin alterations and mast cell mediator symptoms. Most cases have a benign and self-limiting course, but systemic mastocytosis with extracutaneous involvement can occasionally occur. Therapeutic options include H1 antihistamines and educating patients about trigger factors. Epinephrine auto-injectors are recommended for emergency treatment in children with severe symptoms and extensive skin alterations.

MONATSSCHRIFT KINDERHEILKUNDE (2023)

Article Immunology

Slow integrin-dependent migration organizes networks of tissue-resident mast cells

Lukas Kaltenbach, Paloma Martzloff, Sarah K. Bambach, Nadim Aizarani, Michael Mihlan, Alina Gavrilov, Katharina M. Glaser, Manuel Stecher, Roland Thuenauer, Aude Thiriot, Klaus Heger, Katrin Kierdorf, Stephan Wienert, Ulrich H. von Andrian, Marc Schmidt-Supprian, Claus Nerlov, Frederick Klauschen, Axel Roers, Marc Bajenoff, Dominic Gruen, Tim Laemmermann

Summary: The movement of mast cells differs from the general concept of interstitial immune cell migration. Integrin-dependent adhesion plays a crucial role in controlling mast cell movement and localization. Substrate-dependent haptokinesis is important for the tissue organization of resident immune cells.

NATURE IMMUNOLOGY (2023)

Article Allergy

European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives

Peter Valent, Karin Hartmann, Patrizia Bonadonna, Wolfgang Sperr, Marek Niedoszytko, Hanneke C. Kluin-Nelemans, Olivier Hermine, Karl Sotlar, Gregor Hoermann, Boguslaw Nedoszytko, Sigurd Broesby-Olsen, Roberta Zanotti, Magdalena Lange, Michael Doubek, Knut Brockow, Ivan Alvarez-Twose, Judit Varkonyi, Selim Yavuz, Gunnar Nilsson, Deepti Radia, Clive Grattan, Juliana Schwaab, Theo Gillen, Hanneke N. G. Oude Elberink, Hans Haegglund, Frank Siebenhaar, Emir Hadzijusufovic, Vito Sabato, Jiri Mayer, Andreas Reiter, Alberto Orfao, Hans-Peter Horny, Massimo Triggiani, Michel Arock

Summary: In 2002, the European Competence Network on Mastocytosis (ECNM) was established to improve the diagnosis and management of patients with mast cell disorders. It consists of specialized centers and experts dedicated to MC diseases, aiming to distribute information to patients, doctors, and scientists. Over the past 20 years, the ECNM has made significant contributions to the development of diagnostic concepts and treatments for mastocytosis and MC activation disorders. It has also organized meetings and conferences to support research in this field.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2023)

Article Medicine, General & Internal

Development of an RNase H2 Activity Assay for Clinical Screening

Marian Simon Schulz, Cay Bennet Sartorius von Bach, Emilija Marinkovic, Claudia Guenther, Rayk Behrendt, Axel Roers

Summary: As a key enzyme in ribonucleotide excision repair, RNase H2 is crucial for removing single ribonucleotides from DNA to prevent genome damage. Loss of RNase H2 activity is directly linked to the development of autoinflammatory and autoimmune diseases, as well as potential involvement in aging and neurodegeneration. Furthermore, RNase H2 activity can serve as a potential diagnostic and prognostic marker for various types of cancer. However, there is currently no validated method for quantifying RNase H2 activity in clinical settings.

JOURNAL OF CLINICAL MEDICINE (2023)

Article Allergy

Increased TIM-3 and galectin-9 serum levels in patients with advanced systemic mastocytosis

Martina Konantz, Margaret Williams, Tamara Merkel, Antonia Reiss, Stefan Dirnhofer, Sara C. Meyer, Peter Valent, Tracy I. George, Alexandar Tzankov, Karin Hartmann

Summary: This study found that serum levels of TIM-3 and galectin-9 are increased in patients with advanced systemic mastocytosis. Additionally, TIM-3 and galectin-9 are expressed in bone marrow infiltrates in mastocytosis. These findings suggest that TIM-3 and galectin-9 could be explored as diagnostic markers and potential therapeutic targets in systemic mastocytosis, particularly in advanced forms.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Oncology

Diagnosis and treatment of systemic mastocytosis

Juliana Schwaab, Hans-Peter Horny, Karin Hartmann

Summary: Systemic mastocytosis (SM) is a clonal stem cell disorder with a wide range of clinical manifestations and a heterogeneous prognosis. This review explores the challenges in diagnosis, prognostic models, and therapeutic options for this rare disease. The elevated serum tryptase levels are a diagnostic criterion of SM and symptomatic therapy may be applied in all patients. Novel KIT inhibitors have significantly improved overall survival and symptoms in advanced phase disease (AdvSM) patients, and allogeneic stem cell transplantation remains the only curative option.

ONKOLOGIE (2023)

Article Allergy

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies

Peter Schmid-Grendelmeier, Melinda J. Gooderham, Karin Hartmann, George N. Konstantinou, Marc Fellmann, Christopher Koulias, Claire Clibborn, Pinaki Biswas, Patrick M. Brunner

Summary: This article evaluated the efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and allergic comorbidities. The results showed that abrocitinib was effective and safe in managing atopic dermatitis in patients with or without allergic comorbidities.

ALLERGY (2023)

Article Cell Biology

In vivo interrogation of regulatory genomes reveals extensive quasi-insufficiency in cancer evolution

Anja Fischer, Robert Lersch, Niklas de Andrade Kraetzig, Alexander Strong, Mathias J. Friedrich, Julia Weber, Thomas Engleitner, Rupert Oellinger, Hsi-Yu Yen, Ursula Kohlhofer, Irene Gonzalez-Menendez, David Sailer, Liz Kogan, Mari Lahnalampi, Saara Laukkanen, Thorsten Kaltenbacher, Christine Klement, Majdaddin Rezaei, Tim Ammon, Juan J. Montero, Guenter Schneider, Julia Mayerle, Mathias Heikenwaelder, Marc Schmidt-Supprian, Leticia Quintanilla-Martinez, Katja Steiger, Pentao Liu, Juan Cadinanos, George S. Vassiliou, Dieter Saur, Olli Lohi, Merja Heinaeniemi, Nathalie Conte, Allan Bradley, Lena Rad, Roland Rad

Summary: Compared to the loss of tumor-suppressor function, the effects of discrete gene dysregulations caused by non-coding genome alterations are poorly understood. In this study, by perturbing the regulatory genome in mice, the researchers reveal the pervasive roles of subtle gene expression variation in cancer evolution. They identified extensive quasi-insufficiency across different tumors and discovered diverse context dependencies. The study provides important insights into tumor evolution and the tissue-specific effects of non-coding mutations.

CELL GENOMICS (2023)

No Data Available